SGMO News and Press, Sangamo Therapeutics Inc. From 11/21/25

2025-11-21 09:12:07 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway Sangamo Therapeutics GAAP EPS of -$0.11 misses by $...

2025-11-06 23:56:42 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript Sangamo Therapeutics GAAP EPS of -$0.11 misses by $0.11, revenue of $0.6M misses by $33.8M Sangamo Therapeutics Q3 2025 Earnings Preview See...

2025-11-06 23:56:09 ET Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript

2025-11-06 08:06:43 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript Sangamo Therapeutics Q3 2025 Earnings Preview Sangamo Therapeutics falls on CFO retirement Seeking Alpha’s Quant Rating on Sangamo Th...

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Prese...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

2025-11-05 09:59:24 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation Sangamo Therapeutics falls on CFO retirement Seeking Alpha’...

RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company ...

2025-09-12 09:03:18 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation Sangamo Therapeutics Q2 2025 Earnings Preview Sangamo rises after ...

Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated positive mean annualized estimated...